FDA has approved nipocalimab (Imaavytm), a FcRn for use in generalized myasthenia gravis (gMG). It is approved for using in gMG patents who are anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. https://t.co/CaSwCnCK8V https://t.co/A2COjk2hzY
Links:
Johnson & Johnson receives FDA approval for IMAAVYTM (nipocalimab-aahu), a new …
https://www.jnj.com/media-center/press-releases/johnson-johnson-receives-fda-ap…
May-02-2025
